NCT05666271Active, not recruiting
Radiofrequency Ablation for Hepatocellular Carcinoma Using Octopus MP Electrodes
Radiofrequency Ablation for Small Hepatocellular Carcinoma Using Octopus MP Electrodes or Octopus Electrodes With Adjustable Tips: A Prospective Observational Study
Source: ClinicalTrials.gov · Last updated 13 Apr 2026
Brief summary (registry, in English)
This study is to investigate the therapeutic effect and treatment results of radiofrequency ablation using the Octopus MP electrode capable of temperature monitoring and drug injection and a variable-length electrode for treatment of small hepatocellular carcinomas (≤ 3cm).
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 76 (estimated)
- First submitted
- 18 Dec 2022
- Start date
- 29 Aug 2022
- Primary completion date
- 30 Aug 2026
- Lead sponsor
- Seoul National University Hospital
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT05666271
What you commit to
- Study type: Observational
- Planned participants: 76
- From 29 Aug 2022 to the primary completion date, 30 Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- platelet count less than 40,000 per mm3 or International Normalized Ratio (INR) prolongation over 50%
Other
- number of recurrent HCCs, more than 3
- largest HCC size over 3 cm
- presence of vascular invasion by HCC
- presence of extrahepatic metastasis
Who the study is looking for
- Child-Pugh Class A or B
- chronic hepatitis B or chronic hepatitis C or liver cirrhosis
- presence of hepatocellular carcinoma (HCC) after confirmed by pathology or imaging studies including contrast enhanced computed tomography (CT) or magnetic resonance imaging (MRI) according to the Korean Liver Cancer Study Group (KLCSG)-National Cancer Center (NCC) Korea practice guidelines.
- up to 3 lesions, each greater than less than or equal to 3 cm at the time of locoregional treatment.
Age in the registry: 20 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Seoul National University Hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.